Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study aims to assess treatment patterns and outcomes in advanced RCC patients in real world clinical practices across various real world databases. Four databases will be evaluated
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with advanced renal cell carcinoma (RCC) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tyrosine kinase inhibitor (TKI) | Drug | TKIs |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With First Line Treatment Regimen | Number of participants with first line treatment regimen prescribed following a primary and secondary diagnosis of advanced/metastatic disease is reported in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment. | At index (anytime between 1-Apr-2018 and 31-Jul-2022 [approximately 52 months]); data collected and observed retrospectively over 35 months |
| Number of Participants With Monotherapy and Combination Therapy | Participants who received monotherapy and combination therapy by line of therapy is reported in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment. | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months |
| Time to First Line Therapy | Time to first line therapy was defined as length of time (days) from the first RCC diagnosis to first line therapy prescription. Index date was defined as the date of initiation of the aRCC treatment. | From RCC diagnosis to index date (approximately 52 months); data collected and observed retrospectively over 35 months |
| Duration of Treatment According to Each Line of Therapy | Duration of treatment as per each line of therapy is reported in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment. | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months |
| Number of Participants With Treatment Continuation | Treatment continuation was considered when there was no more than (>) 30-day gap (i.e., persistent treatment) for the index medication during follow-up period. Index date was defined as the date of initiation of the aRCC treatment. |
Not provided
Not provided
Inclusion Criteria:
Age 20 years or older in the year of the index first line therapy prescription.
Exclusion Criteria:
Received advanced treatment prior to the study index date.
Not provided
Not provided
Not provided
patients with RCC
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer INC | New York | New York | 10017 | United States |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Not provided
Not provided
Not provided
Not provided
A total of 355 participants were included in the study.
Participants diagnosed with advanced/metastatic renal cell carcinoma (RCC) who initiated treatment for aRCC between 1-Apr-2018 and 31-Jul-2022 were observed. Data was collected retrospectively from various real world claims databases (Truven, Optum, Pharmetrics and the PanTher). Index date was the date of initiation of the aRCC treatment. Data was collected and observed for approximately 35 months (02 December 2019 to 28 October 2022) of this study.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Axitinib + Pembrolizumab | Participants diagnosed with aRCC who initiated treatment with axitinib + pembrolizumab between 1-Apr-2018 and 31-Jul-2022 were included and observed retrospectively in this study. |
| FG001 | Axitinib + Avelumab | Participants diagnosed with aRCC initiated treatment with axitinib + avelumab between 1-Apr-2018 and 31-Jul-2022 were included and observed retrospectively in this study. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Analysis population included all eligible participants whose data were retrieved and observed in this study.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Axitinib + Pembrolizumab | Participants diagnosed with aRCC who initiated treatment with axitinib + pembrolizumab between 1-Apr-2018 and 31-Jul-2022 were included and observed retrospectively in this study. |
| BG001 | Axitinib + Avelumab |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With First Line Treatment Regimen | Number of participants with first line treatment regimen prescribed following a primary and secondary diagnosis of advanced/metastatic disease is reported in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment. | All eligible participants whose data were retrieved and observed in this study. | Posted | Count of Participants | Participants | At index (anytime between 1-Apr-2018 and 31-Jul-2022 [approximately 52 months]); data collected and observed retrospectively over 35 months |
|
For all-cause mortality: From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months. Data for non-serious adverse events and serious adverse events (SAEs) were not collected and evaluated during the study; hence timeframe is not applicable for non-SAEs and SAEs.
This observational retrospective study retrieved data from electronic medical records and claims and the data existed as structured data or combination of existing structured and unstructured data. In these data sources, individual participant data were not retrieved or validated, and it was not possible to link a particular product and medical event for any individual. Thus, the minimum criteria for reporting an adverse event could not be met, hence safety data were not collected and reported.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Axitinib + Pembrolizumab | Participants diagnosed with aRCC who initiated treatment with axitinib + pembrolizumab between 1-Apr-2018 and 31-Jul-2022 were included and observed retrospectively in this study. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClinicalTrials.gov Call Center | Pfizer Inc. | 1-800-718-1021 | ClinicalTrials.gov_Inquires@pfizer.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Dec 1, 2019 | Oct 17, 2023 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D002292 | Carcinoma, Renal Cell |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
| ID | Term |
|---|---|
| D000092004 | Tyrosine Kinase Inhibitors |
| ID | Term |
|---|---|
| D047428 | Protein Kinase Inhibitors |
| D004791 | Enzyme Inhibitors |
| D045504 | Molecular Mechanisms of Pharmacological Action |
| D020228 | Pharmacologic Actions |
Not provided
Not provided
Not provided
Not provided
Not provided
| Immuno-oncology (IO) |
| Drug |
IOs |
|
| From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months |
| Number of Participants With Treatment Interruption | Treatment Interruption was considered in participants with gaps in treatment greater than allowable gap but who restart the same medication with no indication of switching or augmentation. Index date was defined as the date of initiation of the aRCC treatment. | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months |
| Time to Treatment Interruption | Time from index medication to treatment discontinuation for those within treatment interruptions (>30 day gaps). Represents the time between index and end of last treatment, including any treatment gaps. Index date was defined as the date of initiation of the aRCC treatment. | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months |
| Number of Participants With Treatment Switch or Augmentation | Number of participants who had treatment switch or augmentation were reported in this outcome measure. Augmentation was defined as addition of treatment to initial therapy prescribed, i.e, initiation of a new therapy different from the initial therapy while continuation of the initial therapy. Index date was defined as the date of initiation of the aRCC treatment. | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months |
| Number of Participants According to Lines of Therapy | Number of participants as per the lines of treatment were reported in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment. | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months |
| Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Number of participants according to the sequence of therapies received for mRCC were reported in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment. | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months |
| Number of Participants According to Their Status at End of Follow-up | Number of participants according to their status (death, end of enrollment and end of data availability) at end of follow-up were observed and included in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment. | At end of enrollment, follow-up or death (maximum of 52 months) (data collected and observed retrospectively over 35 months) |
| Time to Treatment Failure (TTF) | TTF was defined as the time from first-line therapy start to treatment discontinuation for any reason, including switched, augmented therapy, end of enrollment or death. Index date was defined as the date of initiation of the aRCC treatment. | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months |
| Percentage of Participants With Treatment Discontinuation | Percentage of participants with treatment discontinuation was defined as the percentage of participants with gap in therapy greater than 30 days and who did not begin a new treatment. Index date was defined as the date of initiation of the aRCC treatment. | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months |
| Percentage of Participants Alive at 3 Months | Percentage of participants who were alive at 3 months is reported in this outcome measure. | At 3 months (data collected and observed retrospectively over 35 months) |
| Percentage of Participants Alive at 6 Months | Percentage of participants who were alive at 6 months is reported in this outcome measure. | At 3 months (data collected and observed retrospectively over 35 months) |
| Percentage of Participants Alive at 12 Months | Percentage of participants who were alive at 12 months is reported in this outcome measure. | At 3 months (data collected and observed retrospectively over 35 months) |
| Overall Survival | OS is defined as the length of time from index date to participant's death. Index date was defined as the date of initiation of the aRCC treatment. | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months |
Participants diagnosed with aRCC initiated treatment with axitinib + avelumab between 1-Apr-2018 and 31-Jul-2022 were included and observed retrospectively in this study. |
| BG002 | Total | Total of all reporting groups |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| OG001 |
| Axitinib + Avelumab |
Participants diagnosed with aRCC initiated treatment with axitinib + avelumab between 1-Apr-2018 and 31-Jul-2022 were included and observed retrospectively in this study. |
|
|
| Primary | Number of Participants With Monotherapy and Combination Therapy | Participants who received monotherapy and combination therapy by line of therapy is reported in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment. | All eligible participants whose data were retrieved and observed in this study. Here, 'Number Analyzed' signifies participants evaluable for specified rows. | Posted | Count of Participants | Participants | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months |
|
|
|
| Primary | Time to First Line Therapy | Time to first line therapy was defined as length of time (days) from the first RCC diagnosis to first line therapy prescription. Index date was defined as the date of initiation of the aRCC treatment. | All eligible participants whose data were retrieved and observed in this study. | Posted | Median | Inter-Quartile Range | Days | From RCC diagnosis to index date (approximately 52 months); data collected and observed retrospectively over 35 months |
|
|
|
| Primary | Duration of Treatment According to Each Line of Therapy | Duration of treatment as per each line of therapy is reported in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment. | All eligible participants whose data were retrieved and observed in this study. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows. | Posted | Median | Inter-Quartile Range | Days | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months |
|
|
|
| Primary | Number of Participants With Treatment Continuation | Treatment continuation was considered when there was no more than (>) 30-day gap (i.e., persistent treatment) for the index medication during follow-up period. Index date was defined as the date of initiation of the aRCC treatment. | All eligible participants whose data were retrieved and observed in this study. | Posted | Count of Participants | Participants | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months |
|
|
|
| Primary | Number of Participants With Treatment Interruption | Treatment Interruption was considered in participants with gaps in treatment greater than allowable gap but who restart the same medication with no indication of switching or augmentation. Index date was defined as the date of initiation of the aRCC treatment. | All eligible participants whose data were retrieved and observed in this study. | Posted | Count of Participants | Participants | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months |
|
|
|
| Primary | Time to Treatment Interruption | Time from index medication to treatment discontinuation for those within treatment interruptions (>30 day gaps). Represents the time between index and end of last treatment, including any treatment gaps. Index date was defined as the date of initiation of the aRCC treatment. | All eligible participants whose data were retrieved and observed in this study. Here, 'Overall Number of Participants Analyzed' signified participants evaluable for this outcome measure. | Posted | Median | Inter-Quartile Range | Months | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months |
|
|
|
| Primary | Number of Participants With Treatment Switch or Augmentation | Number of participants who had treatment switch or augmentation were reported in this outcome measure. Augmentation was defined as addition of treatment to initial therapy prescribed, i.e, initiation of a new therapy different from the initial therapy while continuation of the initial therapy. Index date was defined as the date of initiation of the aRCC treatment. | All eligible participants whose data were retrieved and observed in this study. | Posted | Count of Participants | Participants | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months |
|
|
|
| Primary | Number of Participants According to Lines of Therapy | Number of participants as per the lines of treatment were reported in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment. | All eligible participants whose data were retrieved and observed in this study. | Posted | Count of Participants | Participants | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months |
|
|
|
| Primary | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Number of participants according to the sequence of therapies received for mRCC were reported in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment. | All eligible participants whose data were retrieved and observed in this study. | Posted | Count of Participants | Participants | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months |
|
|
|
| Primary | Number of Participants According to Their Status at End of Follow-up | Number of participants according to their status (death, end of enrollment and end of data availability) at end of follow-up were observed and included in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment. | All eligible participants whose data were retrieved and observed in this study. | Posted | Count of Participants | Participants | At end of enrollment, follow-up or death (maximum of 52 months) (data collected and observed retrospectively over 35 months) |
|
|
|
| Primary | Time to Treatment Failure (TTF) | TTF was defined as the time from first-line therapy start to treatment discontinuation for any reason, including switched, augmented therapy, end of enrollment or death. Index date was defined as the date of initiation of the aRCC treatment. | All eligible participants whose data were retrieved and observed in this study. | Posted | Median | 95% Confidence Interval | Months | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months |
|
|
|
| Primary | Percentage of Participants With Treatment Discontinuation | Percentage of participants with treatment discontinuation was defined as the percentage of participants with gap in therapy greater than 30 days and who did not begin a new treatment. Index date was defined as the date of initiation of the aRCC treatment. | All eligible participants whose data were retrieved and observed in this study. | Posted | Number | Percentage of participants | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months |
|
|
|
| Primary | Percentage of Participants Alive at 3 Months | Percentage of participants who were alive at 3 months is reported in this outcome measure. | All eligible participants whose data were retrieved and observed in this study. | Posted | Number | Percentage of participants | At 3 months (data collected and observed retrospectively over 35 months) |
|
|
|
| Primary | Percentage of Participants Alive at 6 Months | Percentage of participants who were alive at 6 months is reported in this outcome measure. | All eligible participants whose data were retrieved and observed in this study. | Posted | Number | Percentage of participants | At 3 months (data collected and observed retrospectively over 35 months) |
|
|
|
| Primary | Percentage of Participants Alive at 12 Months | Percentage of participants who were alive at 12 months is reported in this outcome measure. | All eligible participants whose data were retrieved and observed in this study. | Posted | Number | Percentage of participants | At 3 months (data collected and observed retrospectively over 35 months) |
|
|
|
| Primary | Overall Survival | OS is defined as the length of time from index date to participant's death. Index date was defined as the date of initiation of the aRCC treatment. | All eligible participants whose data were retrieved and observed in this study. | Posted | Median | 95% Confidence Interval | Days | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months |
|
|
|
| 161 |
| 340 |
| 0 |
| 0 |
| 0 |
| 0 |
| EG001 | Axitinib + Avelumab | Participants diagnosed with aRCC initiated treatment with axitinib + avelumab between 1-Apr-2018 and 31-Jul-2022 were included and observed retrospectively in this study. | 11 | 15 | 0 | 0 | 0 | 0 |
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
| D009369 | Neoplasms |
| D007680 | Kidney Neoplasms |
| D014571 | Urologic Neoplasms |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |
| D020164 | Chemical Actions and Uses |
| Monotherapy- Second Line |
|
|
| Monotherapy- Third Line |
|
|
| Monotherapy- Fourth Line |
|
|
| Monotherapy- Fifth Line |
|
|
| Monotherapy- Sixth Line |
|
|
| Combination therapy- First Line |
|
|
| Combination therapy- Second Line |
|
|
| Combination therapy- Third Line |
|
|
| Combination therapy- Fourth Line |
|
|
| Combination therapy- Fifth Line |
|
|
| Combination therapy- Sixth Line |
|
|
| Second Line Therapy |
|
|
| Third Line Therapy |
|
|
| Fourth Line Therapy |
|
|
| Fifth Line Therapy |
|
|
| Sixth Line Therapy |
|
|
| Third Line Therapy |
|
| Fourth Line Therapy |
|
| Fifth Line Therapy |
|
| Sixth Line Therapy |
|
| Avelumab, Axitinib/ Cabozantinib |
|
| Avelumab,Axitinib/ Cabozantinib/ Cabozantinib, Nivolumab/ Tivozanib/ Pazopanib |
|
| Avelumab,Axitinib/ Cabozantinib/ Everolimus, Lenvatinib |
|
| Avelumab,Axitinib/ Cabozantinib/ Pazopanib |
|
| Avelumab, Axitinib/ Ipilimumab, Nivolumab |
|
| Avelumab, Axitinib/ Nivolumab |
|
| Avelumab, Axitinib/ Pembrolizumab |
|
| Axitinib,Pembrolizumab |
|
| Axitinib,Pembrolizumab/ Axitinib (PEM-AXI), leuprolide, Pembrolizumab |
|
| AXI,PEM/ AXI,Leuprolide,PEM/ Abiraterone,AXI,PEM/Abiraterone,Axitinib,Leuprolide, PEM |
|
| AXI, PEM/ AXI, PEM/ Cabozantinib |
|
| AXI, PEM/ Bevacizumab/ Cabozantinib |
|
| AXI, PEM/ Bevacizumab- Awwb/ Bevacizumab/ Temsirolimus/ Bevacizumab- Awwb |
|
| AXI, PEM/ Bevacizumab-Awwb/ Cabozantinib |
|
| AXI, PEM/ Bevacizumab-Awwb, Everolimus |
|
| AXI, PEM/ Cabozantinib |
|
| AXI, PEM/ Cabozantinib/Bevacizumab- Awwb |
|
| AXI, PEM/ Cabozantinib/Cabozantinib, Nivolumab |
|
| AXI, PEM/ Cabozantinib/ Cabozantinib, PEM/ Everolimus, Lenvatinib |
|
| AXI, PEM/ Cabozantinib/ Clinical Study Drug (CSD)/ Everolimus, Lenvatinib/ Belzutifan |
|
| AXI, PEM/ Cabozantinib/ Everolimus, Lenvatinib |
|
| AXI, PEM/ Cabozantinib/ Everolimus, Lenvatinib/ Bevacizumab -Bvzr, Erlotinib |
|
| AXI, PEM/ Cabozantinib/ Everolimus, Lenvatinib/ CSD |
|
| AXI, PEM/ Cabozantinib/ Everolimus,Lenvatinib/ Ipilimumab, Nivolumab |
|
| AXI, PEM/ Cabozantinib/ Everolimus, Lenvatinib, Tivozanib |
|
| AXI, PEM/ Cabozantinib/ Ipilimumab, Nivolumab |
|
| AXI, PEM/ Cabozantinib/ Ipilimumab, Nivolumab/ Everolimus, Lenvatinib |
|
| AXI, PEM/ Cabozantinib/ Pazopanib/ Ipilimumab, Nivolumab |
|
| AXI, PEM/ Cabozantinib/ Pazopanib- Lenvatinib, Pembrolizumab/ Tivozanib |
|
| AXI, PEM/ Cabozantinib/Tivozanib/ Ipilimumab, Nivolumab |
|
| AXI, PEM/ Cabozantinib,CSD |
|
| AXI, PEM/ Cabozantinib,Nivolumab |
|
| AXI, PEM/ Cabozantinib,Nivolumab/ Everolimus,Lenvatinib |
|
| AXI, PEM/ Cabozantinib,Nivolumab,PEM/ Everolimus,Lenvatinib |
|
| AXI, PEM/ Cabozantinib,PEM |
|
| AXI, PEM/Chlorambucil,Obinutuzumab/ Rituximab |
|
| AXI, PEM/ CSD |
|
| AXI, PEM/ CSD/ Cabozantinib |
|
| AXI,PEM/ CSD,Cyclophosphamide,Daratumumab/Hyaluronidase- Fihj,Fludarabine/ Cabozantinib,Nivolumab |
|
| AXI, PEM/ CSD,Cyclophosphamide,Fludarabine/ Cabozantinib,Nivolumab |
|
| Axitinib,Pembrolizumab/CSD,Gemcitabine |
|
| AXI, PEM-Doxorubicin,PEM/ Cabozantinib |
|
| AXI, PEM/ Everolimus |
|
| AXI, PEM/ Everolimus/ Pazopanib |
|
| AXI, PEM/ Everolimus,Lenvatinib |
|
| AXI, PEM/ Everolimus,Lenvatinib/ Cabozantinib/ Everolimus |
|
| AXI, PEM/ Everolimus,Lenvatinib/ Cabozantinib,Nivolumab |
|
| AXI, PEM/ Everolimus,Lenvatinib/ Ipilimumab,Nivolumab |
|
| AXI, PEM/ Everolimus,Lenvatinib,Pembrolizumab |
|
| AXI, PEM/ Gemcitabine,Paclitaxel Protein-Bound,Pembrolizumab |
|
| AXI, PEM/ Hydroxyurea,Pembrolizumab |
|
| AXI, PEM/ Ipilimumab,Nivolumab |
|
| AXI, PEM/ Ipilimumab,Nivolumab/ Cabozantinib |
|
| AXI, PEM/ Ipilimumab,Nivolumab/ Cabozantinib,Ipilimumab,Nivolumab |
|
| Axitinib,Pembrolizumab/ Ipilimumab,Nivolumab/ CSD |
|
| AXI, PEM/ Ipilimumab,Nivolumab/ Everolimus,Lenvatinib |
|
| AXI, PEM/ Lenvatinib |
|
| AXI, PEM/ Lenvatinib, Pembrolizumab |
|
| AXI, PEM/ Leuprolide/ Bicalutamide,Leuprolide |
|
| AXI, PEM/ Nivolumab/ Cabozantinib |
|
| AXI, PEM/ Nivolumab/ Cabozantinib,Nivolumab |
|
| AXI, PEM/ Pazopanib |
|
| AXI, PEM/ Pazopanib/ Cabozantinib/ Everolimus,Lenvatinib/ Sunitinib/ Tivozanib |
|
| AXI, PEM/ Pazopanib/ Cabozantinib,Nivolumab |
|
| AXI, PEM/ Pazopanib/ Everolimus,Lenvatinib |
|
| AXI, PEM/ PEM |
|
| AXI, PEM/ PEM,Sunitinib |
|
| AXI, PEM/ Sunitinib/ Pembrolizumab,Sunitinib |
|
| AXI, PEM/ Sunitinib/Tivozanib/ Cabozantinib/ Tivozanib |
|
| End of data availability |
|